Next-Generation Obesity Peptides
Explore peptide research and guides on next-generation obesity peptides.
Next-Generation Obesity Peptides
Orforglipron: The Oral GLP-1 That Changes Everything
Orforglipron is a non-peptide oral GLP-1 agonist that produced 11.2% weight loss in Phase 3. How Lilly's pill could disrupt the injectable GLP-1 market.
Next-Generation Obesity PeptidesPemvidutide: The GLP-1/Glucagon Dual Agonist for MASH
Pemvidutide targets both GLP-1 and glucagon receptors, cutting liver fat by 54.7% and body weight by 15.6% in Phase 2 trials. Full clinical data here.